Evaluating new biomarkers for diabetic nephropathy: Role of α2-macroglobulin, podocalyxin, α-L-fucosidase, retinol-binding protein-4, and cystatin C

doi:10.4239/wjd.v15.i6.1212

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1912)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

HTML

857

Figures (1-3)

210

Tables (1-5)

132

Sum=1245

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

113

Download

260

Sum=373

Publishing Process of This Article

Item

Count

Browse

Download

190

Sum=218

Jun 15, 2024 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Diabetes. Jun 15, 2024; 15(6): 1212-1225
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1212

Table 1 Diagnostic criteria for diabetes (World Health Organization, 1999)

Diagnostic criteria	Venous plasma glucose levels (mmol/L)
Diabetic symptoms and random blood glucose	≥ 11.1 mmol/L
Fasting plasma glucose	≥ 7.0 mmol/L
Plasma glucose 2 h after oral glucose tolerance test	≥ 11.1 mmol/L

At least one of the three diagnostic criteria needs to be met. If there is no typical “three more and one less”, it needs another test to confirm the diagnosis.

Table 2 Comparison of clinical and laboratory parameters between diabetic nephropathy and non-diabetic nephropathy patients

Parameters	NDN (n = 88)	DN (n = 115)	F/Z value	P value
Age, yr	57.03 ± 10.34	60.57 ± 11.05^a	0.680	0.021
Sex, male, n (%)	58 (65.90)	75 (65.20)	0.011	0.918
BMI, kg/m²	25.69 ± 2.67	26.35 ± 3.72	7.695	0.192
Hypertension, present, n (%)	41 (46.60)	97 (84.30)^a	32.650	< 0.001
Course, yr	8 (3.75, 15.00)	12 (8.00, 20.00)^a	3.666	< 0.001
FPG, mmol/L	6.80 (5.60, 8.10)	6.80 (5.68, 8.70)	0.469	0.639
HbA1c, %	8.82 ± 1.77	8.70 ± 2.39	6.676	0.681
NLR	1.72 (1.34, 2.14)	2.19 (1.70, 3.19)^a	4.547	< 0.001
hs-CRP, mg/L	1.55 (0.72, 3.37)	2.60 (0.95, 7.20)^a	2.293	0.022
TC, mmol/L	4.35 ± 1.03	4.71 ± 1.53^a	8.009	0.045
TG, mmol/L	1.64 (1.08, 2.26)	1.65 (1.12, 2.66)	1.064	0.287
LDL-C, mmol/L	2.53 ± 0.77	2.61 ± 0.96	3.181	0.544
HDL-C, mmol/L	0.99 ± 0.20	0.96 ± 0.23	1.228	0.265
Urea, mmol/L	5.50 (4.63, 6.30)	7.60 (5.80, 11.93)^a	6.726	< 0.001
CysC, mg/L	0.53 (0.45, 0.72)	1.18 (0.65, 1.99)^a	7.419	< 0.001
RBP-4, mg/L	39.99 (30.69, 46.30)	53.20 (41.00, 73.00)^a	6.284	< 0.001
Scr, μmol/L	68.00 (59.00, 79.75)	105.00 (70.00, 199.00)^a	6.525	< 0.001
eGFR, mL·min^-1·1.73 m^-2	95.99 (90.11, 104.82)	57.01 (27.22, 93.84)^a	6.561	< 0.001
UACR, mg/g	6.30 (3.70, 15.45)	446.20 (114.10, 1086.20)^a	11.542	< 0.001
UTP/24 h, g/24 h	0.04 (0.02, 0.08)	1.31 (0.34, 4.07)^a	11.624	< 0.001
U-α2-MG/UCr, mg/g	1.20 (0.86, 2.02)	5.78 (2.00, 17.31)^a	8.110	< 0.001
U-PCX/UCr, μg/g	2.91 (1.48, 5.04)	12.83 (6.25, 42.27)^a	8.817	< 0.001
U-AFU/UCr, nmol/g	0.04 (0.03, 0.07)	0.34 (0.05, 2.14)^a	7.105	< 0.001

^aCompared with the group of NDN, P < 0.05.

DN: Diabetic nephropathy; α2-MG: α2-macroglobulin; PCX: Podocalysin; AFU: α-L-fucosidase; RBP-4: Retinol binding protein-4; CysC: Cystatin C; NDN: Nondiabetic nephropathy; CKD: Chronic kidney disease; UACR: Urinary albumin/creatinine ratio; eGFR: Estimated glomerular filtration rate; hs-CRP: Hypersensitive C-reactive protein; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TG: Triglyceride; TC: Total cholesterol; FPG: Asting plasma glucose; HbA1c: Glycosylated hemoglobin; Urea: Urea nitrogen; SCr: Serum creatinine; UTP/24 h: Urinary total protein/24 h; NLR: Neutrophilic-to-lymphoid ratio; BMI: Body mass index.

Table 3 Partial correlation analysis between cystatin C, retinol-binding protein-4, U-α2- macroglobulin, U-podocalyxin, U-α-L-fucosidase, and clinical indicators

Indicator	CysC		RBP-4		U-α2-MG/UCr		U-PCX/UCr		U-AFU/UCr
Indicator	r	P value	r	P value	r	P value	r	P value	r	P value
UACR	0.730	< 0.001	0.625	< 0.001	0.805	< 0.001	0.639	< 0.001	0.780	< 0.001
eGFR	-0.816	< 0.001	-0.702	< 0.001	-0.711	< 0.001	-0.604	< 0.001	-0.742	< 0.001
CysC	1.000	-	0.693	< 0.001	0.710	< 0.001	0.645	< 0.001	0.692	< 0.001
RBP-4	0.693	< 0.001	1.000	-	0.530	< 0.001	0.432	< 0.001	0.588	< 0.001
U-α2-MG/UCr	0.710	< 0.001	0.530	< 0.001	1.000	-	0.820	< 0.001	0.874	< 0.001
U-PCX/UCr	0.645	< 0.001	0.432	< 0.001	0.820	< 0.001	1.000	-	0.746	< 0.001
U-AFU/UCr	0.692	< 0.001	0.588	< 0.001	0.874	< 0.001	0.746	< 0.001	1.000	-
Scr	0.953	< 0.001	0.680	< 0.001	0.755	< 0.001	0.645	< 0.001	0.715	< 0.001
Urea	0.799	< 0.001	0.651	< 0.001	0.657	< 0.001	0.568	< 0.001	0.703	< 0.001
UTP/24 h	0.665	< 0.001	0.506	< 0.001	0.740	< 0.001	0.523	< 0.001	0.743	< 0.001
NLR	0.417	< 0.001	0.167	0.018	0.311	< 0.001	0.299	< 0.001	0.313	< 0.001
hs-CRP	0.067	0.343	0.079	0.267	0.094	0.186	0.111	0.118	0.087	0.222

Gender and age were adjusted. α2-MG: α2-macroglobulin; PCX: Podocalysin; AFU: α-L-fucosidase; RBP-4: Retinol binding protein-4; CysC: Cystatin C; UACR: Urinary albumin/creatinine ratio; eGFR: Estimated glomerular filtration rate; hs-CRP: Hypersensitive c-reactive protein; Urea: Urea nitrogen; SCr: Serum creatinine; UTP/24 h: Urinary total protein/24 h; NLR: Neutrophilic-to-lymphoid ratio.

Table 4 Evaluation of area under the curve and its 95% confidence interval for various indicators

Indicators waiting to be measured	AUC	Standard error	P value	95% confidence interval
UACR	0.97	0.01	< 0.001	(0.95, 1.00)
eGFR	0.77	0.03	< 0.001	(0.70, 0.84)
CysC	0.80	0.03	< 0.001	(0.75, 0.86)
RBP-4	0.76	0.03	< 0.001	(0.69, 0.82)
U-α2-MG/UCr	0.83	0.03	< 0.001	(0.78, 0.89)
U-PCX/UCr	0.86	0.03	< 0.001	(0.81, 0.91)
U-AFU/UCr	0.79	0.03	< 0.001	(0.73, 0.85)
U-α2-MG/UCr + U-PCX/UCr	0.88	0.03	< 0.001	(0.83, 0.93)
U-PCX/UCr + U-AFU/UCr	0.88	0.03	< 0.001	(0.84, 0.93)
U-α2-MG/UCr + U-AFU/UCr	0.86	0.03	< 0.001	(0.80, 0.91)
U-α2-MG/UCr + U-PCX/UCr + U-AFU/UCr	0.89	0.03	< 0.001	(0.85, 0.94)

α2-MG: α2-macroglobulin; PCX: Podocalysin; AFU: α-L-fucosidase; RBP-4: Retinol binding protein-4; CysC: Cystatin C; UACR: Urinary albumin/creatinine ratio; eGFR: Estimated glomerular filtration rate; AUC: Area under the receiver operating characteristic curve.

Table 5 Optimal diagnostic cut-off points and their sensitivity and specificity for various indicators

Indicators	Optimal diagnostic cut-off points	Sensitivity	Specificity	Youden index
UACR	29.50	0.95	0.98	0.93
eGFR	74.41	0.96	0.58	0.54
CysC	1.11	0.54	0.99	0.53
RBP-4	56.90	0.45	0.98	0.43
U-α2-MG/UCr	3.90	0.55	0.99	0.54
U-PCX/UCr	4.81	0.84	0.75	0.59
U-AFU/UCr	0.18	0.63	0.92	0.55
U-α2-MG/UCr + U-PCX/UCr	-	0.86	0.76	0.62
U-PCX/UCr + U-AFU/UCr	-	0.75	0.86	0.61
U-α2-MG/UCr + U-AFU/UCr	-	0.68	0.90	0.58
U-α2-MG/UCr + U-PCX/UCr + U-AFU/UCr	-	0.89	0.75	0.64

Citation: Li JJ, Sa RL, Zhang Y, Yan ZL. Evaluating new biomarkers for diabetic nephropathy: Role of α2-macroglobulin, podocalyxin, α-L-fucosidase, retinol-binding protein-4, and cystatin C. World J Diabetes 2024; 15(6): 1212-1225
URL: https://www.wjgnet.com/1948-9358/full/v15/i6/1212.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i6.1212